SAB Biotherapeutics
SABS
39 hedge funds and large institutions have $1.71M invested in SAB Biotherapeutics in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 3 increasing their positions, 7 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
3% more funds holding
Funds holding: 38 → 39 (+1)
0.18% less ownership
Funds ownership: 0.95% → 0.77% (-0.18%)
29% less capital invested
Capital invested by funds: $2.42M → $1.71M (-$706K)
57% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Manhattan
New York
|
+$176K |
| 2 |
VF
Virtu Financial
New York
|
+$9.49K |
| 3 |
TSS
Two Sigma Securities
New York
|
+$8.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.94K |
| 5 |
GI
GS Investments
Minneapolis,
Minnesota
|
+$1.26K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$140K |
| 2 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$122K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$51.1K |
| 4 |
AWM
AE Wealth Management
Topeka,
Kansas
|
-$11K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$6.75K |
SABS Hedge Fund Activity: Q1 2023 in Review
39 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q1 2023, worth a combined $1.71M — down 29% from $2.42M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SABS positions and 6 closed out — a net gain of 1 holder — while 3 added to existing stakes and 7 trimmed.
The largest buyer was First Manhattan, opening a new position worth an estimated $176K. The largest seller was Shaolin Capital Management, exiting entirely with an estimated $140K sold.
- 39 institutional investors held SAB Biotherapeutics (SABS) as of Q1 2023, up from 38 in Q4 2022.
- Funds reported $1.71M of SAB Biotherapeutics stock for Q1 2023, down 29% quarter-over-quarter.
- 7 funds opened new SAB Biotherapeutics positions in Q1 2023 and 6 closed out, a net change of +1 holder.
- The largest SAB Biotherapeutics buyer in Q1 2023 was First Manhattan, an estimated $176K added.
- The largest SAB Biotherapeutics seller in Q1 2023 was Shaolin Capital Management, an estimated $140K sold.
Based on aggregated 13F filings for Q1 2023.